Preclinical Evaluation of Anti-ROR1 CAR T-cells Employing a ROR1 Binding scFv Derived  From the Clinical Stage mAb Cirmtuzumab (Prussak et al.,  2020 ASCO-SITC Clinical Immuno-Oncology Symposium)